Navigation Links
Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting
Date:12/3/2008

SOUTH SAN FRANCISCO, Calif., Dec. 3 /PRNewswire/ -- Portola Pharmaceuticals, a biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular disease, inflammatory disease and cancer, today announced that data related to the Company's series of novel compounds that inhibit spleen tyrosine kinase (Syk) and its novel universal Factor Xa inhibitor antidote will be presented at the annual meeting of the American Society of Hematology (ASH) at the Moscone Center in San Francisco during December 6-9, 2008.

Portola's Syk inhibitor program is focused on developing specific oral inhibitors of this key signaling pathway, which modulate inflammation, certain cancers and thrombosis. The Company plans to study its compounds initially in rheumatoid arthritis and non-Hodgkin's Lymphoma and eventually intends to explore their potential in other inflammatory diseases and cancers. Portola is developing its universal Factor Xa inhibitor antidote to neutralize the effect of small molecule Factor Xa inhibitors in patients experiencing major bleeding and for patients undergoing emergent or elective surgery.

Details of the ASH presentations are below and full abstracts can be viewed on the ASH website at http://www.hematology.org.

Syk Inhibitor Program

"Specific Inhibition of Syk is Sufficient to Disrupt Proliferation and Survival of Non-Hodgkin's Lymphoma Cell Lines without Concomitant Inhibition of JAK" (abstract # 1794)

Saturday, December 6, 5:30 PM

Hall A (Moscone Center)

"PRT060318, a Novel Syk Inhibitor, Prevents Heparin-Induced Thrombocytopenia in a Transgenic Mouse Model" (abstract # 269)

Monday, December 8, 7:00 AM

3007-3009-3011 - West (Moscone Center)

"Specific Pharmacological Targeting of the Syk Kinase Activity in Platelets: A Novel, Safe Anti-Thrombotic Strategy" (abstract # 409)

Monday, December 8, 11:00 AM

3002-3004 - West (Moscone Center)

"Inhibition of Syk Activity is Sufficient for Inhibitory Effect in Animal Models of Autoimmune Diseases" (abstract # 680)

    Monday, December 8, 5:15 PM
    2006-2008 - West (Moscone Center)

    Factor Xa Inhibitor Antidote

"Recombinant Antidote for Reversal of Anticoagulation by Factor Xa Inhibitors" (abstract # 983)

    Saturday, December 6, 5:30 PM
    Hall A (Moscone Center)

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals develops innovative therapeutics based on targets with established proof of concept that are engineered to provide significant advances over current treatments for cardiovascular and inflammatory diseases and cancer.

Portola's two lead Phase II compounds, betrixaban, an oral Factor Xa inhibitor and PRT060128, an ADP receptor antagonist, target the global multi- billion dollar antithrombotic market. Both product candidates have best-in- class features versus current and novel agents in development and address the hospital, specialty, and chronic care markets. The Company's earlier-stage programs are leveraging its chemistry capability to develop specific Syk and JAK inhibitors to treat cancer and inflammatory diseases. The company also has a novel Factor Xa inhibitor antidote program with the potential to help manage the more than 20 million patients expected to be treated with anticoagulants worldwide in the next decade. For additional information, visit http://www.portola.com.

     Contact:
     Mardi Dier - CFO, Portola Pharmaceuticals
     650-246-7236
     mdier@portola.com

     Julie Normart, Invigorate Communications
     415-946-1087
     jnormart@invigoratepr.com

'/>"/>
SOURCE Portola Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
2. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
3. Novel Technology Breaks Through Cancer Pain
4. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
5. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
6. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
7. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
8. NIST team develops novel method for nanostructured polymer thin films
9. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
10. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
11. European Expert Consortium Combines Forces to Develop a Novel Pandemic Influenza Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 3, 2016 ... Assessing Developers and Producers of Those Competitor Biologics  ... to Companies, Activities and Prospects ,  Who ... companies? And what are their sales potentials? Discover, ... you see results, trends, opportunities and revenue forecasting. ...
(Date:5/3/2016)... , ... May 03, 2016 , ... According to world ... for definitive prostate cancer treatment, patients traditionally had two main treatment options: surgery or ... would be made. , New technology has enabled doctors to administer higher doses ...
(Date:5/2/2016)... , May 2, 2016 Q ... its technology partner Mannin Research Inc. will be attending ... which takes place from May 1-5, 2016 in ... be meeting with its vendors and research partners. The ... development goals and other collaborative opportunities for the MAN-01 ...
(Date:5/2/2016)... ... May 02, 2016 , ... StarNet Communications Corp, ( http://www.starnet.com/ ) ... of three Secure Remote Desktop modules to its flagship X-Win32 PC X server. ... Unix servers to the user’s PC over encrypted SSH. , Traditionally, users of PC ...
Breaking Biology Technology:
(Date:3/11/2016)... -- http://www.apimages.com ) - --> http://www.apimages.com ) ... AP Images ( http://www.apimages.com ) - Germany ... the new refugee identity cards. DERMALOG will be unveiling this device, ... Hanover next week.   --> Germany ... produce the new refugee identity cards. DERMALOG will be unveiling this ...
(Date:3/9/2016)... Germany , March 9, 2016 ... country,s government identified that more than 23,000 public service ... or had been receiving their salary unlawfully.    ... African country,s government identified that more than 23,000 public ... name or had been receiving their salary unlawfully.    ...
(Date:3/3/2016)... and DE SOTO, Kansas , March ... Detection Plus® to offer Oncimmune,s Early CDT®-Lung, a ... early detection of lung cancer Early CDT®-Lung ... and individuals. --> Early CDT®-Lung test to ... --> Oncimmune, a leader in early cancer ...
Breaking Biology News(10 mins):